| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $4,878,800 | 29 | 100 |
| Brady James Aloysius | director | 0 | $0 | 1 | $60,036 | $-60,036 |
| HALKUFF DAWN | director | 0 | $0 | 1 | $121,886 | $-121,886 |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | director | 0 | $0 | 2 | $203,922 | $-203,922 |
| PERSKY MARLA | director | 0 | $0 | 2 | $211,043 | $-211,043 |
| Shannon John Patrick Jr | See Remarks | 0 | $0 | 2 | $349,658 | $-349,658 |
| Pieper Steven | See Remarks | 0 | $0 | 4 | $468,176 | $-468,176 |
| JOHNSON JOHN | director | 0 | $0 | 2 | $1.07M | $-1.07M |
| McCulloch Kevin | See Remarks | 0 | $0 | 4 | $1.09M | $-1.09M |
| Hecht Beth | See Remarks | 0 | $0 | 11 | $1.31M | $-1.31M |
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Over the last 12 months, insiders at Xeris Biopharma Holdings, Inc. have bought $0 and sold $4.88M worth of Xeris Biopharma Holdings, Inc. stock.
On average, over the past 5 years, insiders at Xeris Biopharma Holdings, Inc. have bought $302,183 and sold $2.18M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $109,475 was made by McCulloch Kevin (See Remarks) on 2025‑06‑13.
| 2026-09-01 | Sale | McCulloch Kevin | See Remarks | 15,000 0.0087% | $8.49 | $127,308 | +1.78% | |
| 2026-09-01 | Sale | Pieper Steven | See Remarks | 5,000 0.0029% | $8.50 | $42,500 | +1.78% | |
| 2026-09-01 | Sale | Hecht Beth | See Remarks | 16,666 0.0097% | $8.49 | $141,434 | +1.78% | |
| 2026-08-12 | Sale | Pieper Steven | See Remarks | 5,000 0.0029% | $8.50 | $42,500 | +1.30% | |
| 2026-08-03 | Sale | McCulloch Kevin | See Remarks | 15,000 0.0087% | $8.02 | $120,240 | +4.86% | |
| 2026-08-03 | Sale | Hecht Beth | See Remarks | 16,666 0.0096% | $8.01 | $133,553 | +4.86% | |
| 2026-07-07 | Sale | Pieper Steven | See Remarks | 27,600 0.0163% | $8.52 | $235,276 | -5.15% | |
| 2026-07-06 | Sale | Pieper Steven | See Remarks | 17,400 0.0102% | $8.50 | $147,900 | +1.37% | |
| 2026-07-01 | Sale | McCulloch Kevin | See Remarks | 90,000 0.0523% | $8.03 | $722,511 | +5.75% | |
| 2026-07-01 | Sale | Hecht Beth | See Remarks | 16,666 0.0097% | $8.03 | $133,860 | +5.75% | |
| 2026-06-04 | Sale | JOHNSON JOHN | director | 15,000 0.0086% | $6.09 | $91,422 | +35.53% | |
| 2026-06-04 | Sale | BORMANN-KENNEDY BARBARA-JEAN ANNE | director | 16,000 0.0092% | $6.09 | $97,507 | +35.53% | |
| 2026-06-04 | Sale | HALKUFF DAWN | director | 20,000 0.0115% | $6.09 | $121,886 | +35.53% | |
| 2026-06-03 | Sale | PERSKY MARLA | director | 15,500 0.009% | $5.90 | $91,433 | +41.43% | |
| 2026-06-01 | Sale | Hecht Beth | See Remarks | 16,667 0.0096% | $6.06 | $100,982 | +37.07% | |
| 2026-05-01 | Sale | Hecht Beth | See Remarks | 16,667 0.01% | $6.23 | $103,805 | +27.39% | |
| 2026-04-01 | Sale | Hecht Beth | See Remarks | 16,667 0.0096% | $5.99 | $99,859 | +14.90% | |
| 2026-03-30 | Sale | Brady James Aloysius | director | 10,834 0.0062% | $5.54 | $60,036 | +23.48% | |
| 2026-03-02 | Sale | Hecht Beth | See Remarks | 16,667 0.0103% | $6.25 | $104,086 | +6.40% | |
| 2026-02-02 | Sale | Hecht Beth | See Remarks | 16,667 0.0102% | $7.45 | $124,147 | -9.24% |
| Shannon John Patrick Jr | See Remarks | 2705346 1.567% | $23.08M | 6 | 2 | +19.99% |
| McCulloch Kevin | See Remarks | 1639208 0.9495% | $13.98M | 1 | 4 | +58.85% |
| Pieper Steven | See Remarks | 1356053 0.7855% | $11.57M | 2 | 4 | +20.95% |
| Hecht Beth | See Remarks | 1127796 0.6533% | $9.62M | 3 | 12 | +37.91% |
| JOHNSON JOHN | director | 683083 0.3957% | $5.83M | 0 | 3 | |
| PERSKY MARLA | director | 126500 0.0733% | $1.08M | 1 | 2 | +52.24% |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | director | 126500 0.0733% | $1.08M | 0 | 2 | |
| HALKUFF DAWN | director | 95000 0.055% | $810,350.00 | 1 | 2 | +32.42% |
| Brady James Aloysius | director | 89166 0.0516% | $760,585.98 | 0 | 1 | |
| Redmile Group, LLC | 10 percent owner | 3000642 1.7381% | $25.6M | 2 | 0 | <0.0001% |
| Edick Paul R | See Remarks | 2288064 1.3253% | $19.52M | 10 | 0 | +1.38% |
| Palmetto Partners, Ltd. | 10 percent owner | 2110061 1.2222% | $18M | 1 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 856470 0.4961% | $7.31M | 1 | 10 | <0.0001% |
| PRESTRELSKI STEVEN | Chief Scientific Officer | 569780 0.33% | $4.86M | 0 | 11 | |
| SHERMAN JEFFREY W | director | 219188 0.127% | $1.87M | 1 | 1 | +32.07% |
| Deutsch Barry M. | See Remarks | 39359 0.0228% | $335,732.27 | 2 | 0 | +5.12% |
| Schmid John P. | director | 25200 0.0146% | $214,956.00 | 5 | 0 | +56.98% |
| JOHNSON KENNETH ERLAND | See Remarks | 6115 0.0035% | $52,160.95 | 2 | 0 | +5.12% |
$8,217,280 | 112 | 46.33% | $1.68B | |
$831,902,292 | 108 | 9.34% | $1.3B | |
Xeris Biopharma Holdings, Inc. (XERS) | $61,893,001 | 38 | 19.63% | $1.47B |
$530,111,731 | 35 | 8.69% | $1.57B | |
$4,431,947 | 22 | 36.10% | $1.6B | |
$135,656,796 | 20 | 30.67% | $1.68B | |
$108,588,651 | 14 | 29.35% | $1.71B | |
$81,819,942 | 13 | -52.16% | $1.49B | |
$2,314,489 | 11 | -0.78% | $1.37B | |
$140,543,039 | 10 | 0.77% | $1.29B | |
$1,229,070 | 10 | 23.53% | $1.37B | |
$38,624,786 | 9 | 1.26% | $1.36B | |
$4,623,072 | 7 | 11.07% | $1.51B | |
$49,165,200 | 7 | 12.92% | $1.26B | |
$19,683,752 | 7 | 6.05% | $1.33B | |
$112,382,168 | 4 | -48.89% | $1.36B | |
$25,999,974 | 4 | 0.00% | $1.44B | |
$1,011,808 | 4 | 52.60% | $1.68B | |
$33,624,000 | 2 | -50.37% | $1.52B |
| Increased Positions | 117 | +42.86% | 16M | +16.28% |
| Decreased Positions | 119 | -43.59% | 13M | -13.7% |
| New Positions | 37 | New | 3M | New |
| Sold Out Positions | 42 | Sold Out | 4M | Sold Out |
| Total Postitions | 271 | -0.73% | 101M | +2.58% |
| Blackrock, Inc. | $87,669.00 | 7.19% | 11.93M | +391,378 | +3.39% | 2025-09-30 |
| Vanguard Group Inc | $72,235.00 | 5.92% | 9.83M | +10,980 | +0.11% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $42,923.00 | 3.52% | 5.84M | +2M | +52.26% | 2025-09-30 |
| Geode Capital Management, Llc | $30,430.00 | 2.49% | 4.14M | +489,486 | +13.41% | 2025-09-30 |
| State Street Corp | $27,477.00 | 2.25% | 3.74M | -44,871 | -1.19% | 2025-09-30 |
| Qube Research & Technologies Ltd | $24,070.00 | 1.97% | 3.27M | +185,063 | +5.99% | 2025-09-30 |
| Morgan Stanley | $23,665.00 | 1.94% | 3.22M | -422,883 | -11.61% | 2025-09-30 |
| Nuveen, Llc | $20,785.00 | 1.7% | 2.83M | +227,432 | +8.75% | 2025-09-30 |
| Driehaus Capital Management Llc | $19,251.00 | 1.58% | 2.62M | +548,054 | +26.46% | 2025-09-30 |
| Rosalind Advisors, Inc. | $13,199.00 | 1.08% | 1.8M | -359,828 | -16.69% | 2025-09-30 |